应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
AZN 阿斯利康
已收盘 12-22 16:00:00 EST
91.55
+0.19
+0.21%
盘后
91.55
+0.00
0.00%
19:33 EST
最高
91.86
最低
90.63
成交量
464.90万
今开
90.81
昨收
91.36
日振幅
1.34%
总市值
2,839亿
流通市值
2,827亿
总股本
31.01亿
成交额
4.25亿
换手率
0.15%
流通股本
30.88亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
阿斯利康肺癌试验药物组合未达到主要目标
环球市场播报 · 12-22 22:12
阿斯利康肺癌试验药物组合未达到主要目标
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
时代财经 · 12-22 16:55
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
阿斯利康入局，Pan-KRAS抑制剂技术路线之争开始逆转
智通财经 · 12-22 08:45
阿斯利康入局，Pan-KRAS抑制剂技术路线之争开始逆转
加科思-B(01167)附属与阿斯利康订立许可与合作协议，以开发及商业化泛KRAS抑制剂JAB-23E73
智通财经网 · 12-21 19:58
加科思-B(01167)附属与阿斯利康订立许可与合作协议，以开发及商业化泛KRAS抑制剂JAB-23E73
默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持
智通财经 · 12-20
默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持
阿斯利康甲磺酸奥希替尼片启动II期临床 适应症为不适合或拒绝化疗的EGFR常见突变阳性III期不可切除NSCLC患者
新浪财经 · 12-19
阿斯利康甲磺酸奥希替尼片启动II期临床 适应症为不适合或拒绝化疗的EGFR常见突变阳性III期不可切除NSCLC患者
荷声科技完成Pre-A轮融资
医药魔方 · 12-19
荷声科技完成Pre-A轮融资
美国FDA批准Enhertu联合疗法用于一线HER2阳性乳腺癌治疗
环球市场播报 · 12-16
美国FDA批准Enhertu联合疗法用于一线HER2阳性乳腺癌治疗
持续深耕血液肿瘤领域 阿斯利康旗下BTK抑制剂片剂纳入医保目录
广州日报新花城 · 12-15
持续深耕血液肿瘤领域 阿斯利康旗下BTK抑制剂片剂纳入医保目录
医保覆盖、创新迭代、本土深耕：阿斯利康血液肿瘤按下“加速键”
21世纪经济报道 · 12-10
医保覆盖、创新迭代、本土深耕：阿斯利康血液肿瘤按下“加速键”
TD Cowen上调阿斯利康目标价至105美元
格隆汇 · 12-10
TD Cowen上调阿斯利康目标价至105美元
独家报道：美国FDA官员通知默沙东、赛诺菲安万特和阿斯利康的RSV抗体疗法将接受新的安全审查
美股速递 · 12-09
独家报道：美国FDA官员通知默沙东、赛诺菲安万特和阿斯利康的RSV抗体疗法将接受新的安全审查
利普卓®乳腺癌适应症纳入国家医保目录
DoNews · 12-07
利普卓®乳腺癌适应症纳入国家医保目录
阿斯利康乳腺癌新药卡匹色替片纳入国家医保
格隆汇 · 12-07
阿斯利康乳腺癌新药卡匹色替片纳入国家医保
港股异动 | 和铂医药-B(02142)午后涨近4% 公司与阿斯利康深化推进全球战略合作
智通财经 · 12-02
港股异动 | 和铂医药-B(02142)午后涨近4% 公司与阿斯利康深化推进全球战略合作
港股异动 | 和铂医药-B(02142)再涨超4% 与阿斯利康深化合作 共同研发新一代肿瘤生物疗法
智通财经 · 11-27
港股异动 | 和铂医药-B(02142)再涨超4% 与阿斯利康深化合作 共同研发新一代肿瘤生物疗法
阿斯利康投资20亿美元用于美国生物制品生产，同时RSV疫苗持久性与阿尔茨海默病药物试验面临挑战AstraZeneca Invests $2 Billion in US Biologics Manufacturing as RSV Vaccine Durability and Alzheimer’s Drug Trials Face Challenges
动脉网 · 11-25
阿斯利康投资20亿美元用于美国生物制品生产，同时RSV疫苗持久性与阿尔茨海默病药物试验面临挑战AstraZeneca Invests $2 Billion in US Biologics Manufacturing as RSV Vaccine Durability and Alzheimer’s Drug Trials Face Challenges
港股异动 | 和铂医药-B(02142)涨近5% 与阿斯利康进一步拓展合作范围 开发ADC及T细胞衔接器疗法
智通财经 · 11-25
港股异动 | 和铂医药-B(02142)涨近5% 与阿斯利康进一步拓展合作范围 开发ADC及T细胞衔接器疗法
阿斯利康：将在马里兰州投资20亿美元扩大美国业务
环球市场播报 · 11-24
阿斯利康：将在马里兰州投资20亿美元扩大美国业务
和铂医药：与阿斯利康深化合作，共同研发新一代肿瘤生物疗法
南方财经网 · 11-24
和铂医药：与阿斯利康深化合作，共同研发新一代肿瘤生物疗法
加载更多
公司概况
公司名称：
阿斯利康
所属市场：
NASDAQ
上市日期：
--
主营业务：
阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。
发行价格：
--
{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":91.55,"timestamp":1766437200000,"preClose":91.36,"halted":0,"volume":4648995,"hourTrading":{"tag":"盘后","latestPrice":91.55,"preClose":91.55,"latestTime":"19:33 EST","volume":682847,"amount":62515030.5026,"timestamp":1766450011492},"delay":0,"floatShares":3088302520,"shares":3101451738,"eps":3.009339,"marketStatus":"已收盘","change":0.19,"latestTime":"12-22 16:00:00 EST","open":90.81,"high":91.855,"low":90.63,"amount":425329411.69368,"amplitude":0.013408,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.009339,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":5,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NASDAQ","adjPreClose":91.36,"dividendRate":0.017079,"preHourTrading":{"tag":"盘前","latestPrice":90.85,"preClose":91.36,"latestTime":"09:29 EST","volume":21459,"amount":1955688.49695,"timestamp":1766413799999},"postHourTrading":{"tag":"盘后","latestPrice":91.55,"preClose":91.55,"latestTime":"19:33 EST","volume":682847,"amount":62515030.5026,"timestamp":1766450011492},"volumeRatio":0.710553,"impliedVol":0.2449,"impliedVolPercentile":0.22},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2593433677","title":"阿斯利康肺癌试验药物组合未达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2593433677","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593433677?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:12","pubTimestamp":1766412720,"startTime":"0","endTime":"0","summary":"阿斯利康表示，其试验性药物ceralasertib与已获批的癌症治疗药物Imfinzi的组合，在一项针对晚期肺癌的后期临床试验中未能达到主要目标。 这家英国制药公司周一表示，研究结果显示，与局部晚期或转移性非小细胞肺癌患者的标准疗法相比，ceralasertib组合未能达到总体生存率这一主要目标。 阿斯利康表示，ceralasertib和Imfinzi的组合总体上耐受性良好，没有出现新的安全性担忧。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-22/doc-inhcsvvf6086289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","LU2462157665.USD","LU2236285917.USD","LU0889565916.HKD","LU2417539215.USD","LU2456880835.USD","LU0109394709.USD","LU1829250122.USD","BK4568","AZN","LU0320765992.SGD","BK4588","BK4585"],"gpt_icon":0},{"id":"2593448816","title":"获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448816","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593448816?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:55","pubTimestamp":1766393727,"startTime":"0","endTime":"0","summary":"12月21日晚间，加科思药业（01167.HK）宣布，已就其自主研发的泛KRAS（Pan-KRAS）抑制剂JAB-23E73与阿斯利康（AZN.US）达成合作协议。根据协议，阿斯利康将获得该产品在中国以外市场的独家开发和商业化权利。在中国市场，加科思将与阿斯利康共同开发和商业化该产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598339468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4568","LU0109394709.USD","LU1829250122.USD","AZN","BK4585","LU0320765992.SGD","LU2236285917.USD","BK4588","LU0889565916.HKD","LU2456880835.USD","LU2417539215.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2593171901","title":"阿斯利康入局，Pan-KRAS抑制剂技术路线之争开始逆转","url":"https://stock-news.laohu8.com/highlight/detail?id=2593171901","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593171901?lang=zh_cn&edition=full","pubTime":"2025-12-22 08:45","pubTimestamp":1766364328,"startTime":"0","endTime":"0","summary":"当阿斯利康以20亿美元接手加科思 Pan-KRAS抑制剂项目的全球开发后，这场竞赛的本质已经发生变化。更重要的是，对阿斯利康来说，一个安全性更好的分子，更有可能在未来KRAS抑制剂联合治疗版图中占据优势。对阿斯利康来说，Pan-KRAS 的终极目标并不仅仅是在某个小人群中证明“能用”，而是成为联用时代的底座。相比之下，加科思 Pan-KRAS抑制剂 采用的是更为传统、成熟的小分子路线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK4585","LU0320765992.SGD","BK4568","LU1829250122.USD","LU2417539215.USD","LU0889565916.HKD","BK4007","BK4588","01167","LU2462157665.USD","LU0109394709.USD","LU2456880835.USD","LU2236285917.USD","AZN"],"gpt_icon":0},{"id":"2593124204","title":"加科思-B(01167)附属与阿斯利康订立许可与合作协议，以开发及商业化泛KRAS抑制剂JAB-23E73","url":"https://stock-news.laohu8.com/highlight/detail?id=2593124204","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593124204?lang=zh_cn&edition=full","pubTime":"2025-12-21 19:58","pubTimestamp":1766318290,"startTime":"0","endTime":"0","summary":"加科思-B(01167)公布，该集团的非全资附属公司北京加科思新药研发有限公司与AstraZeneca \nAB(阿斯利康)已订立许可与合作协议，以开发及商业化泛KRAS抑制剂JAB-23E73。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_30.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_30.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","LU1829250122.USD","LU2236285917.USD","BK4585","LU0109394709.USD","LU2456880835.USD","LU0889565916.HKD","LU2462157665.USD","LU0320765992.SGD","01167","BK4007","AZN","BK1161","BK4568","BK4588","LU2417539215.USD"],"gpt_icon":0},{"id":"2592139231","title":"默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139231","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592139231?lang=zh_cn&edition=full","pubTime":"2025-12-20 07:00","pubTimestamp":1766185200,"startTime":"0","endTime":"0","summary":"美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。在此次协议中，最受市场关注的是施贵宝的让利承诺。特朗普在周五的公开活动上表示，今年7月他致信要求降价的17家大型制药企业中，已有14家同意大幅下调药价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2acbaf8fbf691a451fa9ea170ee88816","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2106854487.HKD","LU1116320737.USD","SG9999015341.SGD","BK4007","BK4588","IE00BLSP4239.USD","LU1093756325.SGD","LU0648001328.SGD","LU0211331839.USD","GILD","LU1941712264.USD","LU1057294990.SGD","IE00BBT3K403.USD","SG9999014575.USD","LU1201861249.SGD","IE0009355771.USD","LU1571399168.USD","LU2023250504.SGD","LU2089984988.USD","LU1035773651.USD","LU1061106388.HKD","LU2468319806.SGD","LU0267386448.USD","LU1023059063.AUD","LU0985320562.USD","IE00B1BXHZ80.USD","LU0098860793.USD","LU2361044865.SGD","LU0289739699.SGD","LU0861579265.USD","LU1989772923.USD","LU2361044949.HKD","LU0096364046.USD","LU1430594728.SGD","BK4532","BMY","AMGN","LU2360032135.SGD","IE00BJT1NW94.SGD","JNJ","LU1093756168.USD","LU0265550359.USD","LU0985481810.HKD","LU1868836914.USD","LU1868836757.USD","SG9999001176.USD","LU0130517989.USD","IE000M9KFDE8.USD","LU0114720955.EUR","IE00BN8TJ469.HKD","LU2324357040.USD","LU2461242641.AUD","LU0265550946.USD","NVS","ABBV","LU1670711040.USD","LU0203347892.USD","LU2125154935.USD","IE00BLSP4452.SGD","LU0456855351.SGD","REGN","LU0203345920.USD","LU2125154778.USD","SG9999002232.USD","LU1868837300.USD","IE00B2B36J28.USD","SG9999014559.SGD","LU1066053197.SGD","BK4533","LU1032466523.USD","SNY","LU1699723380.USD","LU2361045086.USD","LU0965508806.USD","LU0321505439.SGD","LU1670711123.USD","SG9999002224.SGD","BK4550","LU0130102774.USD","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU1323610961.USD","LU1983299246.USD","BK4581","LU0882574055.USD","LU1069347547.HKD","GSK","LU0965509010.AUD","LU0225771236.USD","LU1291159041.SGD","SG9999001176.SGD","SG9999013999.USD","LU0070302665.USD","LU0238689110.USD","SGXZ57979304.SGD","LU1261432733.SGD","LU1934455863.HKD","IE00BJJMRZ35.SGD","LU0237698245.USD","LU0058720904.USD","BK4585","LU0122379950.USD","LU0306806265.USD","LU1929549753.HKD","LU0965509101.SGD","LU0208291251.USD","LU0106261372.USD","SG9999014542.SGD","LU1941712348.USD","LU2242646821.SGD","LU1670710588.SGD","LU1868836591.USD","LU1974910355.USD","BK4559","LU2023250843.SGD","LU1162221912.USD","LU2112291526.USD","LU0225284248.USD","IE00BFXG1179.USD","SG9999001440.SGD","IE0002141913.USD","LU0234572021.USD","LU0306807586.USD","LU1066051498.USD","LU1934455277.USD","LU1116320901.HKD","LU1917777945.USD","LU1989772840.SGD","LU1868837136.USD","LU0965509283.SGD","BK4516","LU2242652126.USD","AZN","LU0061475181.USD","LU1037948897.HKD","LU1074936037.SGD","LU1037948541.HKD","LU1585245621.USD","SG9999015358.SGD","BK4534","LU0320765646.SGD","SG9999014567.USD","LU0006306889.USD","LU0477156953.USD","LU1989771016.USD","LU1670710661.SGD","LU0320765489.SGD","LU1718418525.SGD","MRK","LU1934455194.USD","04332","LU0980610538.SGD","LU1066051811.HKD","ROG","IE00B4R5TH58.HKD","LU0266013472.USD","LU1066051225.USD","LU0868494617.USD","LU0321505868.SGD","IE00BSNM7G36.USD"],"gpt_icon":1},{"id":"2592199939","title":"阿斯利康甲磺酸奥希替尼片启动II期临床 适应症为不适合或拒绝化疗的EGFR常见突变阳性III期不可切除NSCLC患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2592199939","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592199939?lang=zh_cn&edition=full","pubTime":"2025-12-19 18:03","pubTimestamp":1766138580,"startTime":"0","endTime":"0","summary":"本次试验目的是评估不适合或拒绝化疗的EGFRm阳性III期不可切除NSCLC患者在放疗前使用奥希替尼作为诱导治疗及在放疗后继续使用奥希替尼直至疾病进展的有效性。甲磺酸奥希替尼片为化学药物，适应症为不适合或拒绝化疗的EGFR常见突变阳性III期不可切除NSCLC患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219185751a6b6da17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219185751a6b6da17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","III","BK4007","BK4568","LU2462157665.USD","BK4585","BK4588","LU2417539215.USD","AZN","LU0320765992.SGD","BK4134","LU2456880835.USD","LU0109394709.USD","LU2236285917.USD","LU1829250122.USD"],"gpt_icon":0},{"id":"2592954199","title":"荷声科技完成Pre-A轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2592954199","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592954199?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:07","pubTimestamp":1766128034,"startTime":"0","endTime":"0","summary":"阿斯利康中金医疗产业基金近日宣布完成对杭州荷声科技有限公司Pre-A轮融资。中金资本董事总经理沈圆江表示：“荷声科技自成立以来，专注于突破高端超声核心技术，展现出显著成长潜力，同时在新一代超声系统发展趋势中具备前瞻性布局。本轮Pre-A融资完成，是对其技术实力和行业前景的积极认可。我们相信，在产业资源的协同下，荷声科技将稳步推进产品落地与规模化应用，持续引领中国高端医疗超声创新发展。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219152604a6b5f722&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219152604a6b5f722&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU1829250122.USD","LU2236285917.USD","LU2456880835.USD","LU2462157665.USD","BK4568","BK4585","AZN","LU0320765992.SGD","LU2417539215.USD","BK4007","BK4588","LU0889565916.HKD"],"gpt_icon":0},{"id":"2591359889","title":"美国FDA批准Enhertu联合疗法用于一线HER2阳性乳腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2591359889","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591359889?lang=zh_cn&edition=full","pubTime":"2025-12-16 23:45","pubTimestamp":1765899900,"startTime":"0","endTime":"0","summary":"FDA批准阿斯利康（AZN）与第一三共（Daiichi Sankyo，TYO：4568）的fam-trastuzumab deruxtecan（Enhertu）联合帕妥珠单抗（pertuzumab）用于一线治疗，因DESTINY-Breast09试验显示其中位无进展生存期（PFS）达40.7个月，优于标准THP方案的26.9个月；帕妥珠单抗由罗氏（SWX：ROG）销售。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-16/doc-inhaziff7927164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4211","BK4007","LU0320765992.SGD","BK4568","LU2417539215.USD","BK4588","LU0889565916.HKD","LU2456880835.USD","PFS","LU0109394709.USD","LU1829250122.USD","LU2462157665.USD","BK4585","AZN","BK4195","LU2236285917.USD"],"gpt_icon":0},{"id":"2591661576","title":"持续深耕血液肿瘤领域 阿斯利康旗下BTK抑制剂片剂纳入医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2591661576","media":"广州日报新花城","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591661576?lang=zh_cn&edition=full","pubTime":"2025-12-15 01:14","pubTimestamp":1765732464,"startTime":"0","endTime":"0","summary":"政策加持、市场需要之下，药企正在不断突破以提升创新药的可及性。12月7日，在国家医保局公布的2025年医保目录中，阿斯利康旗下BTK抑制剂的升级剂型（片剂）被正式纳入医保，标志着阿斯利康在血液肿瘤领域发展迈入新阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591031847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2417539215.USD","BK4007","AZN","LU1829250122.USD","LU0320765992.SGD","BK4568","LU2456880835.USD","BK4585","BK4588","LU0889565916.HKD","LU2236285917.USD","LU2462157665.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2590538907","title":"医保覆盖、创新迭代、本土深耕：阿斯利康血液肿瘤按下“加速键”","url":"https://stock-news.laohu8.com/highlight/detail?id=2590538907","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590538907?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:43","pubTimestamp":1765374221,"startTime":"0","endTime":"0","summary":"血液肿瘤是最常见的恶性肿瘤之一，近年来发病率持续走高。世界卫生组织（WHO）数据显示，全球血液肿瘤新发患者数量由2015年的113.3万增长至2021年的130.5万，预计2030年增长至154.6万；中国新发患者同步增长，预计2030年增长至30万。庞大的患者基数下，跨国药企与本土创新药企纷纷加速布局，推动血液肿瘤在精准诊断、预后分层及靶向治疗等方面取得快速进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512103587919519.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587919519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0109394709.USD","BK4588","LU0889565916.HKD","LU2417539215.USD","BK4007","LU2456880835.USD","LU1829250122.USD","LU0320765992.SGD","LU2462157665.USD","LU2236285917.USD","BK4585","AZN","BK4568"],"gpt_icon":0},{"id":"2590372841","title":"TD Cowen上调阿斯利康目标价至105美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590372841","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590372841?lang=zh_cn&edition=full","pubTime":"2025-12-10 11:23","pubTimestamp":1765337030,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2417539215.USD","BK4585","LU2462157665.USD","BK4207","BK4568","TD","LU1829250122.USD","LU2456880835.USD","AZN","LU0109394709.USD","LU0889565916.HKD","BK4007","LU2236285917.USD","LU0320765992.SGD","BK4588","BK4566"],"gpt_icon":0},{"id":"1153946041","title":"独家报道：美国FDA官员通知默沙东、赛诺菲安万特和阿斯利康的RSV抗体疗法将接受新的安全审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1153946041","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153946041?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:01","pubTimestamp":1765278094,"startTime":"0","endTime":"0","summary":"独家报道：美国FDA官员通知默沙东、赛诺菲安万特和阿斯利康的RSV抗体疗法将接受新的安全审查","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","MRK","LU2461242641.AUD","IE0034235188.USD","LU1035773651.USD","SG9999014542.SGD","LU1496350171.SGD","IE00B2B36J28.USD","LU1015430645.USD","LU1481600234.SGD","LU1934455194.USD","LU0997586432.USD","LU0265550946.USD","LU0784385840.USD","LU0889566641.SGD","BK5011","LU1066051811.HKD","LU1989772840.SGD","BK4534","LU0211326839.USD","LU0969580561.USD","LU1917777945.USD","LU0972486137.USD","LU0234572021.USD","LU0784385170.HKD","LU1880407215.USD","LU0122379950.USD","LU0070302665.USD","03165","LU1019632923.USD","BK4585","LU1051770623.HKD","LU2125154778.USD","LU2089284900.SGD","LU2468319806.SGD","LU0047473722.SGD","LU0526926950.USD","LU0957799991.USD","LU1023059063.AUD","LU0265550359.USD","LU1093756168.USD","SG9999002232.USD","SG9999013999.USD","LU1093756325.SGD","LU0310800379.SGD","SG9999014575.USD","LU0545039389.USD","LU1941712264.USD","LU0310799852.SGD","LU0106261372.USD","AZN","LU1267930490.SGD","LU1066051225.USD","LU0738911758.USD","LU0965509283.SGD","LU1481599808.USD","LU2108987350.USD","LU1929549753.HKD","LU0320765646.SGD","LU0211327993.USD","LU0345777147.USD","LU2114397693.USD","LU0496365809.HKD","LU0965509010.AUD","LU2023250843.SGD","LU0963555726.SGD","LU1057294990.SGD","LU1974910355.USD","LU0211328371.USD","LU0823416689.USD","LU0757432116.USD","SG9999001176.USD","LU0960981461.USD","LU0708994859.HKD","BK4588","SG9999015358.SGD","LU1430594728.SGD","IE00B4R5TH58.HKD","LU0985320562.USD","LU1989771016.USD","LU1487256676.USD","LU0238689110.USD","LU0976567544.SGD","LU1934455863.HKD","LU0211331839.USD","LU0128525929.USD","LU2324357040.USD","LU1116320737.USD","LU1153584641.USD","LU0784383803.USD","LU1267930227.SGD","LU2279689827.SGD","LU2106854487.HKD","LU0052756011.USD","BK4559","SG9999001176.SGD","LU1983299246.USD","LU0289739699.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0964806797.USD","LU1003076772.USD","LU0345777659.USD","LU2360032135.SGD","BK4516","LU0640478417.SGD","LU0882574055.USD","LU0575583348.USD","LU2023251221.USD","LU2293690249.USD","BK4550","LU0006306889.USD","LU1291159041.SGD","BK4007","LU0499090636.EUR","LU0077335932.USD","LU2112291526.USD","LU0128525689.USD","SG9999014567.USD","LU2089283258.USD","LU2089984988.USD","SNY","LU1301847155.USD","IE00BBT3K403.USD","LU1119994496.HKD","LU1585245621.USD","LU0203347892.USD","LU1941712348.USD","LU2133065610.SGD","LU0029864427.USD","LU2125154935.USD","LU0171293334.USD","LU1571399168.USD","LU0114720955.EUR","IE00BJT1NW94.SGD","LU1061106388.HKD","LU1037948897.HKD","LU1104425308.USD","IE00B1BXHZ80.USD","IE00BN8TJ469.HKD","LU1064927863.SGD","LU1003077747.HKD","IE000M9KFDE8.USD","LU0208291251.USD","LU2023250504.SGD","LU0965508806.USD","LU0792757196.USD","LU0965509101.SGD","LU2361044865.SGD","LU2361044949.HKD","LU0432979614.USD","IE0009355771.USD","LU0320765489.SGD","IE00BSNM7G36.USD","LU0047473722.EUR","IE00B3T34201.USD","LU1078025761.USD","LU0823399737.USD","LU1699723380.USD","LU0098860793.USD","LU1162221912.USD","LU0211326755.USD","LU0553294199.USD","LU0310800965.SGD","LU1153585028.USD","LU0058720904.USD","LU1066051498.USD","IE00BKPKM643.USD","LU1267930813.SGD","LU1261432733.SGD","IE00BJJMRZ35.SGD","LU0661504455.SGD","LU2293690082.USD","LU1037948541.HKD","LU0158827948.USD","LU0889565080.SGD","LU1323610961.USD","BK4533","LU1084165304.USD","SG9999014559.SGD","LU1267930573.SGD","LU0011850046.USD","LU1066053197.SGD","LU1019634622.SGD","LU1989772923.USD","LU1814569148.SGD","LU1880407132.USD","LU0949170772.SGD","SG9999001440.SGD","LU0557290698.USD","LU0861579265.USD","LU1116320901.HKD","LU1069347547.HKD","LU1934455277.USD","IE00BLSP4239.USD","SGXZ57979304.SGD","LU0784384876.USD","LU0949170426.SGD","LU2091194634.USD","LU2539964713.USD","LU2361045086.USD","LU0266013472.USD","SG9999002224.SGD","SG9999015341.SGD","LU1496350502.SGD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2589383244","title":"利普卓®乳腺癌适应症纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589383244","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589383244?lang=zh_cn&edition=full","pubTime":"2025-12-07 17:44","pubTimestamp":1765100643,"startTime":"0","endTime":"0","summary":"阿斯利康与默沙东联合宣布，利普卓®（奥拉帕利）乳腺癌适应症被纳入国家医保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207174917a728d171&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207174917a728d171&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0058720904.USD","LU0211331839.USD","LU1974910355.USD","IE00BBT3K403.USD","LU1983299246.USD","BK4550","IE00B1BXHZ80.USD","LU0098860793.USD","SGXZ57979304.SGD","LU0965509101.SGD","LU1941712348.USD","LU2324357040.USD","LU1934455277.USD","LU0965508806.USD","LU0070302665.USD","BK4533","LU1162221912.USD","LU0203345920.USD","LU0238689110.USD","LU2023250843.SGD","LU2089984988.USD","SG9999001176.USD","LU0106261372.USD","LU1430594728.SGD","SG9999014575.USD","LU0320765489.SGD","LU2360032135.SGD","LU0203347892.USD","LU0985320562.USD","SG9999014559.SGD","SG9999002232.USD","IE00BJJMRZ35.SGD","LU0265550359.USD","SG9999014542.SGD","LU1934455194.USD","AZN","LU1934455863.HKD","BK4585","IE0002141913.USD","SG9999002224.SGD","LU1989771016.USD","LU1291159041.SGD","LU1929549753.HKD","LU1066051811.HKD","LU2461242641.AUD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","SG9999001176.SGD","LU2023250504.SGD","SG9999015341.SGD","SG9999001440.SGD","IE0009355771.USD","IE000M9KFDE8.USD","LU1037948897.HKD","LU1061106388.HKD","LU1699723380.USD","LU2468319806.SGD","IE00BLSP4452.SGD","LU0234572021.USD","LU2361044949.HKD","MRK","LU1037948541.HKD","LU1585245621.USD","LU1093756168.USD","IE00BN8TJ469.HKD","BK4516","LU1989772840.SGD","SG9999014567.USD","LU0208291251.USD","LU0265550946.USD","LU1989772923.USD","LU0320765646.SGD","LU1093756325.SGD","LU1066051225.USD","IE00B2B36J28.USD","LU1069347547.HKD","LU1917777945.USD","IE00BLSP4239.USD","LU0965509283.SGD","LU1116320901.HKD","LU1023059063.AUD","LU1066051498.USD","LU2106854487.HKD","LU1066053197.SGD","BK4559","LU0965509010.AUD","LU2361045086.USD","LU1571399168.USD","LU0006306889.USD","LU1116320737.USD","SG9999015358.SGD","LU0861579265.USD","LU2125154778.USD","LU1941712264.USD","LU0289739699.SGD","LU1035773651.USD","LU0122379950.USD","BK4007","BK4588","BK4534","IE00BSNM7G36.USD","LU1057294990.SGD","LU2361044865.SGD","LU0266013472.USD","LU2125154935.USD","LU2112291526.USD","SG9999013999.USD"],"gpt_icon":0},{"id":"2589754428","title":"阿斯利康乳腺癌新药卡匹色替片纳入国家医保","url":"https://stock-news.laohu8.com/highlight/detail?id=2589754428","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589754428?lang=zh_cn&edition=full","pubTime":"2025-12-07 14:04","pubTimestamp":1765087462,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4568","LU2236285917.USD","LU0320765992.SGD","LU0889565916.HKD","LU1829250122.USD","LU2417539215.USD","LU2456880835.USD","AZN","LU2462157665.USD","BK4588","LU0109394709.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2588737081","title":"港股异动 | 和铂医药-B(02142)午后涨近4% 公司与阿斯利康深化推进全球战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2588737081","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588737081?lang=zh_cn&edition=full","pubTime":"2025-12-02 13:54","pubTimestamp":1764654851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B午后涨近4%，截至发稿，涨3.15%，报13.76港元，成交额3342.44万港元。消息面上，和铂医药近日宣布，将更新与深化推进其与阿斯利康于2025年3月建立的全球战略合作。根据协议，阿斯利康将在未来四年内，每年持续向和铂医药提名研发项目，并获得这些项目的授权许可选择权，彰显双方合作关系的持续深化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU0109394709.USD","LU2462157665.USD","LU2417539215.USD","BK1574","BK4568","BK1161","BK4588","LU2456880835.USD","AZN","LU2236285917.USD","02142","LU1829250122.USD","LU0320765992.SGD","BK4007","BK4585","LU0889565916.HKD"],"gpt_icon":0},{"id":"2586876290","title":"港股异动 | 和铂医药-B(02142)再涨超4% 与阿斯利康深化合作 共同研发新一代肿瘤生物疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2586876290","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586876290?lang=zh_cn&edition=full","pubTime":"2025-11-27 10:18","pubTimestamp":1764209891,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B再涨超4%，截至发稿，4.25%，报14.22港元，成交额2784.77万港元。消息面上，和铂医药发布公告，宣布将更新与深化推进其与阿斯利康于2025年3月建立的全球战略合作。根据协议，阿斯利康将在未来四年内，每年持续向和铂医药提名研发项目，并获得这些项目的授权许可选择权，彰显双方合作关系的持续深化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1583","BK4585","LU0320765992.SGD","BK4568","LU1829250122.USD","LU2417539215.USD","LU0889565916.HKD","02142","BK4007","BK4588","LU2462157665.USD","LU0109394709.USD","LU2456880835.USD","LU2236285917.USD","AZN"],"gpt_icon":0},{"id":"2586715874","title":"阿斯利康投资20亿美元用于美国生物制品生产，同时RSV疫苗持久性与阿尔茨海默病药物试验面临挑战AstraZeneca Invests $2 Billion in US Biologics Manufacturing as RSV Vaccine Durability and Alzheimer’s Drug Trials Face Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2586715874","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586715874?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:28","pubTimestamp":1764080880,"startTime":"0","endTime":"0","summary":"报告显示，老年人接种RSV疫苗后保护效果的持久性正在随时间下降。The waning effectiveness of RSV vaccines raises concerns about long-term protection for older populations, prompting further evaluation of vaccine durability. AstraZeneca’s substantial investment underscores its commitment to expanding biologics capabilities within the U.S., with plans to bolster production infrastructure significantly.RSV疫苗效力的减弱引发了对老年人群长期保护的担忧，促使人们进一步评估疫苗的持久性。阿斯利康的巨额投资凸显了其致力于扩展在美国的生物制品能力，并计划大幅加强生产基础设施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511252230349519bdfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511252230349519bdfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4585","LU1093756325.SGD","LU0109394709.USD","LU0154236417.USD","BK4588","LU1093756168.USD","LU2456880835.USD","BK4599","BK4568","AZN","BK4532","LU2462157665.USD","BK4007","LU2417539215.USD","LU0320765992.SGD","NVO","LU2236285917.USD","IE00BKVL7J92.USD","LU1829250122.USD","LU0889565916.HKD"],"gpt_icon":1},{"id":"2586341050","title":"港股异动 | 和铂医药-B(02142)涨近5% 与阿斯利康进一步拓展合作范围 开发ADC及T细胞衔接器疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2586341050","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586341050?lang=zh_cn&edition=full","pubTime":"2025-11-25 10:23","pubTimestamp":1764037381,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B(02142)涨近5%，截至发稿，涨4.92%，报13.62港元，成交额1542.11万港元。消息面上，11月24日，和铂医药-B发布公告，有关公司的间接全资附属公司和铂医药(上海)有限责任公司(和铂上海)与AstraZeneca PLC (AstraZeneca)订立合作、选择权及许可协议，于2025年11月24日，经修订和铂上海与 AstraZeneca订立的合作协议后，订约双方的合作范围进一步扩展，旨在结合两家公司的专业知识，共同发现及开发包括抗体偶联药物(ADC)及T细胞衔接器在内的新一代生物疗法。经济条款与合作协议项下建立的财务框架仍然一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK1583","LU2236285917.USD","BK4568","BK1574","LU1829250122.USD","BK4585","BK4231","LU0889565916.HKD","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","BK4080","BK4588","LU0109394709.USD","BK1161","BK4007","LU2417539215.USD","AZN","02142"],"gpt_icon":0},{"id":"2585245016","title":"阿斯利康：将在马里兰州投资20亿美元扩大美国业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2585245016","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585245016?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:33","pubTimestamp":1763976780,"startTime":"0","endTime":"0","summary":"阿斯利康表示，计划投资20亿美元扩大该公司在马里兰州的业务，这是该公司今年早些时候宣布的一项500亿美元美国投资的一部分。 该公司称，位于盖瑟斯堡的新临床生产设施将扩大公司在当地的业务版图。阿斯利康预计该基地将于2029年启用，创造100个工作岗位，保留400个职位，并创造1000个建筑相关工作岗位。7月份，该公司承诺在美国投入500亿美元用于药品生产和研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-11-24/doc-infypaav5656509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","LU0109394709.USD","BK4007","BK4585","BK4568","LU2236285917.USD","LU2456880835.USD","LU1829250122.USD","LU0320765992.SGD","LU0889565916.HKD","LU2417539215.USD","LU2462157665.USD","AZN"],"gpt_icon":0},{"id":"2585436143","title":"和铂医药：与阿斯利康深化合作，共同研发新一代肿瘤生物疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2585436143","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585436143?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:28","pubTimestamp":1763944103,"startTime":"0","endTime":"0","summary":"南方财经11月24日电，据和铂医药消息，和铂医药将更新与深化推进其与阿斯利康于2025年3月建立的全球战略合作，共同发现和开发包括抗体偶联药物（ADC）和T细胞衔接器（TCE）在内的新一代生物疗法。根据协议，阿斯利康将在未来四年内，每年持续向和铂医药提名研发项目，并获得这些项目的授权许可选择权，彰显双方合作关系的持续深化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511243572260322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2462157665.USD","BK4007","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK1583","LU2236285917.USD","LU2456880835.USD","02142","LU1829250122.USD","BK1161","BK4585","AZN","BK4568","BK1574","BK4588","LU2417539215.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.0266},{"period":"3month","weight":0.1977},{"period":"6month","weight":0.3061},{"period":"1year","weight":0.4178},{"period":"ytd","weight":0.3944}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001428},{"month":2,"riseRate":0.40625,"avgChangeRate":-0.017129},{"month":3,"riseRate":0.5625,"avgChangeRate":0.027992},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018335},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007278}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}